471 patents
Page 20 of 24
Utility
Therapeutic Particles with Peptide Boronic Acid or Boronate Ester Compounds and Methods of Making and Using Same
19 Aug 20
Disclosed herein are compositions for treating and preventing diseases such as myeloma and lymphoma, where the compositions include a biocompatible, therapeutic polymeric nanoparticle having a boronate ester compound or a peptide boronic acid compound, and a biodegradable polymer.
Mir Mukkaram Ali, Maria Conceicao Figueiredo, Jeffrey Hrkach, Young-Ho Song, James Wright, Stephen E. Zale
Filed: 18 Oct 17
Utility
Dihydropyridophthalazinone Inhibitors of Poly(adp-ribose)polymerase (Parp)
19 Aug 20
Bing WANG, Daniel CHU
Filed: 12 Dec 19
Utility
Dihydro-pyrrolo-pyridine Derivatives
19 Aug 20
Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Christopher Ryan Butler, Adam Matthew Gilbert, Erik Alphie Lachapelle, Laura Ann McAllister, Daniel Paul Uccello, Lei Zhang
Filed: 13 Jun 18
Utility
GLP-1 Receptor Agonists and Uses Thereof
12 Aug 20
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
Filed: 28 Apr 20
Utility
Compositions and Methods for Eliciting an Immune Response Against Clostridium Difficile
12 Aug 20
In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof.
Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G.K. Donald, Michael James Flint, Nicholas Randolph Everard Kitchin, Justin Keith Moran, Louise Pedneault, Michael W. Pride, Mark Edward Ruppen, Christopher Frederick Webber
Filed: 13 Sep 18
Utility
Combination of a PARP Inhibitor and a PD-1 Axis Binding Antagonist
12 Aug 20
This invention relates to a method of treating cancer by administering a PARP inhibitor in combination with a PD-1 axis binding antagonist to a patient in need thereof.
John Andrew Blake-Haskins, Christoffel Hendrik Boshoff, Rossano Cesari, Dimitry Serge Antoine Nuyten, Ross Anthony Stewart, Fabian Zohren
Filed: 9 Oct 18
Utility
CDK2 Inhibitors
5 Aug 20
Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton
Filed: 27 Jan 20
Utility
Glycoconjugation Processes and Compositions
5 Aug 20
The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
Jianxin Gu, Jin-hwan Kim, Avvari Krishna Prasad, Yu-ying Yang
Filed: 27 Jan 20
Utility
Immunogenic Glycoprotein Conjugates
5 Aug 20
Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
Filed: 19 Apr 20
Utility
Human Cytomegalovirus GB Polypeptide
5 Aug 20
The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB).
Philip Ralph Dormitzer, Ye Che, Xiaoyuan Sherry Chi, Seungil Han, Kyle Paul Heim, Thomas Richard Jones, Yuhang Liu, Xiayang Qiu, Xinzhen Yang, Xiaojie Yao, Matthew Curtis Griffor, Jennifer Anne Nicki
Filed: 18 Dec 19
Utility
Daptomycin Formulations and Uses Thereof
29 Jul 20
Lyophilized daptomycin formulations having improved reconstitution times are provided.
Jim Alexiou, Andrew Malcolm Knill, Noel Norris, Darryl Whittaker
Filed: 14 Apr 20
Utility
Immunogenic Compositions for Use in Pneumococcal Vaccines
29 Jul 20
An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates.
David Cooper, Kathrin Ute Jansen, Michael William Pride
Filed: 8 Apr 20
Utility
Method of Cell Culture
29 Jul 20
A method of cell culture comprising providing cells in a cell culture medium to start a cell culture process, and, maintaining at least one metabolite selected from 3-(4-hydroxyphenyl)lactate, 4-hydroxyphenylpyruvate, phenyllactate, indolelactate, indolecarboxylic acid, homocysteine, 2-hydroxybutyric acid, isovalerate and formate below a concentration C1 in the cell culture medium, wherein C1 is 3 mM and/or (ii) maintaining at least one amino acid selected from phenylalanine, tyrosine, tryptophan, methionine, leucine, serine, threonine and glycine below a concentration C2 in the cell culture medium, wherein C2 is 2 mM.
Gregory Walter Hiller, Bhanu Chandra Mulukutla
Filed: 19 Dec 19
Utility
Capped and Uncapped Antibody Cysteines, and Their Use In Antibody-drug Conjugation
22 Jul 20
An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
Xiaotian Zhong, Amarnauth Shastrie Prashad, Ronald William Kriz, Tao He, Will Somers, Wenge Wang, Leo Joseph Letendre
Filed: 2 Mar 20
Utility
Recombinant Vaccinia Virus and Methods of Use Thereof
15 Jul 20
The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus; and compositions comprising the replication-competent, recombinant oncolytic vaccinia virus.
Douglas Hanahan, David H. Kirn, Liliana Maruri Avidal, Michael D. Eisenbraun, Joseph J. Binder, Clare Lees
Filed: 8 Jan 20
Utility
Tofacitinib Oral Sustained Release Dosage Forms
1 Jul 20
The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof.
Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
Filed: 12 Mar 20
Utility
5,7-DIHYDRO-PYRROLO-PYRIDINE Derivatives
1 Jul 20
Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Laura Ann McAllister, Erik Alphie LaChapelle, Adam Matthew Gilbert
Filed: 20 Feb 20
Utility
Novel Polymorphic Forms of a TGFBeta Inhibitor
24 Jun 20
The present invention relates to novel crystalline polymorphic and amorphous form of 4-(2-(5-chloro-2-fluorophenyl) -5-isopropylpyridin-4-ylamino)-N-(1,3-dihydroxypropan-2-yl) nicotinamide and to methods for their preparation; and the invention is also directed to pharmaceutical compositions containing at least one polymorphic form and to the therapeutic or prophylactic use of such polymorphic forms and compositions.
Anand Venkataramana Sistla, Iain David Roy, Andrew Robbins
Filed: 16 Dec 19
Utility
Tissue Factor Pathway Inhibitor Antibodies and Uses Thereof
17 Jun 20
The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof.
Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
Filed: 16 Dec 19
Utility
Circulating Tumor Cell Assay
17 Jun 20
Methods for the detection, enumeration and analysis of circulating tumor cells expressing insulin-like growth factor-1 receptors (IGF-1R) are disclosed.
Antonio GUALBERTO, Maria Luisa PACCAGNELLA, Carrie L. MELVIN, Madeline I. REPOLLET, David CHIANESE, Mark Carle CONNELLY, Leonardus Wendelinus Mathias Marie TERSTAPPEN
Filed: 7 Jul 19